
    
      The aim of the FAST project in general is to develop novel recombinant allergen-based
      therapeutics for the treatment of food allergy. The chosen approach is to modify recombinant
      allergens into hypo-allergenic molecules to decrease the risk of anaphylactic side-effects
      and to allow administration of higher doses leading to better efficacy.
    
  